Contact
Please use this form to send email to PR contact of this press release:
TLC Submits Investigational New Drug (IND) Application for TLC19 Inhalable Liposomal Hydroxychloroquine for COVID-19
TO:
Please use this form to send email to PR contact of this press release:
TLC Submits Investigational New Drug (IND) Application for TLC19 Inhalable Liposomal Hydroxychloroquine for COVID-19
TO: